MonteKart FX in Clinical Context
MonteKart FX is Earkart's oral combination tablet for the management of allergic rhinitis, bringing together montelukast sodium 10 mg, a leukotriene receptor antagonist, and fexofenadine hydrochloride 120 mg, a second-generation antihistamine. It extends the division's allergy-care range from intranasal therapy into physician-directed oral treatment.
Allergic rhinitis involves more than a runny or blocked nose. It is an allergen-triggered inflammatory response in which several chemical mediators — including histamine and leukotrienes — contribute to sneezing, itching, watery discharge and congestion. That is why physicians managing allergic rhinitis sometimes choose therapies that address more than one mediator pathway, selecting single or combination treatment based on each patient's presentation.
The choice between an intranasal spray, an oral tablet or a combination of approaches — and the decision to use a fixed-dose combination such as montelukast with fexofenadine — is a clinical judgement. MonteKart FX is a prescription product, to be used only under the advice of a Registered Medical Practitioner, with dosage as directed by the physician. Earkart provides this page as product information for healthcare professionals and trade partners, not as self-medication guidance.
Within the Earkart ENT portfolio, MonteKart FX completes the allergic rhinitis line alongside FlutiKart and FlutiKart OX nasal sprays, with OxyKart and NasoKart supporting congestion relief and daily nasal hygiene respectively. The range is manufactured at a WHO-GMP certified facility, consistent with the division's specialist-led, compliance-first positioning.
